Literature DB >> 8651392

Medium aperture meso-caval shunts reliably prevent recurrent variceal hemorrhages.

C H Scudamore1, S R Erb, C Morris, A Hemming, A Poostizadeh, A K Buczkowski, N Caron.   

Abstract

BACKGROUND: Objectives of partial medium aperture mesocaval shunts (MCS) include reduction of portal hypertension to prevent recurrent variceal hemorrhage, preservation of portal flow through liver while maintaining an intact porta hepatis to facilitate a future liver transplant (OLTx). PATIENTS AND METHODS: Fifteen patients were retrospectively analyzed to review the indications for the procedure, its short- and long-term complications as well as patency and functional status of the shunt. They were followed for a period of 21 months.
RESULTS: The perioperative and long-term mortality rate was 0%. Rebleeding rate perioperatively and in follow-up was 0%. Early shunt nonfunction was 13% and post-shunt encephalopathy (PSE) was 20%. The encephalopathy was grade I to II and controlled medically. Abdominal ultrasound and Doppler confirmed 13 patent shunts (2 patients did not agree to ultrasound) with preserved hepatopetal flow in 10.
CONCLUSIONS: Medium aperture MCS utilizing ringed polytetrafluoroethylene (PTFE) grafts safely and reliably prevent recurrent variceal hemorrhage. Encephalopathy is infrequent and mild. This technique preserves the portal venous anatomy making a future OLTx technically easier.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8651392     DOI: 10.1016/S0002-9610(97)89610-9

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  2 in total

Review 1.  Percutaneous Portosystemic Shunts: TIPS and Beyond.

Authors:  Leigh C Casadaban; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

2.  Small-diameter mesocaval shunts: a 10-year evaluation.

Authors:  M A Mercado; H Orozco; E Guillén-Navarro; E Acosta; L M López-Martínez; C Hinojosa; J Hernández; M Tielve
Journal:  J Gastrointest Surg       Date:  2000 Sep-Oct       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.